The British Society for Rheumatology Guideline for the Management of Systemic Lupus Erythematosus in Adults

Caroline Gordon; Maame-Boatemaa Amissah-Arthur; Mary Gayed; Sue Brown; Ian N. Bruce; David D'Cruz; Benjamin Empson; Bridget Griffiths; David Jayne; Munther Khamashta; Liz Lightstone; Peter Norton; Yvonne Norton; Karen Schreiber; David Isenberg


Rheumatology. 2018;57(1):e1-e45. 

In This Article

Recommendations for the Management of Mild SLE

  1. Treatments to be considered for the management of mild non–organ-threatening disease include the disease-modifying drugs HCQ (1 ++/A) and MTX (1+/A), and short courses of NSAIDs (3/D) for symptomatic control. These drugs allow for the avoidance of or dose reduction of CSs (SOA 94%).

  2. Prednisolone treatment at a low dose of ⩽7.5 mg/day may be required for maintenance therapy (2+/C). Topical preparations may be used for cutaneous manifestations, and IA injections for arthritis (4/D) (SOA 93%).

  3. High–Sun Protection Factor (SPF) UV-A and UV-B sunscreen are important in the management and prevention of UV radiation–induced skin lesions (2 ++/B). Patients must also be advised about sun avoidance and the use of protective clothing (4/D) (SOA 97%).